Pan-European MS patient platform providing disease expertise, patient community access, and advocacy capacity to pharmaceutical and health research consortia.
The European Multiple Sclerosis Platform (EMSP) is the pan-European umbrella organization representing national MS patient societies across Europe, giving collective voice to people living with Multiple Sclerosis in research, policy, and clinical innovation. In research consortia, they bring three things that purely academic or industrial partners cannot: direct access to the MS patient community across Europe, grounded understanding of unmet patient needs, and credibility for disseminating results to patients and caregivers. Their H2020 participation spans both advanced drug delivery research (N2B-patch, nose-to-brain MS therapies) and health system reform (DO-IT, big data for better patient outcomes), confirming their strategic role as a connector between cutting research and real patient impact. They do not conduct lab science — they ensure research consortia stay anchored to actual patient priorities and can reach the people who matter most.
Both N2B-patch and DO-IT address MS-relevant challenges — antibody delivery for MS treatment and big data for neurological disease outcomes — confirming EMSP as the MS disease reference point in consortia.
N2B-patch (IMI2, 2017–2021) is an Innovative Medicines Initiative project, a funding scheme requiring meaningful patient organization involvement at every stage from protocol design to dissemination.
DO-IT (RIA, 2017–2019) focused on big data for better healthcare outcomes and policy innovation, areas where patient organizations provide real-world evidence and policy advocacy leverage.
As a platform organization with member societies in multiple EU countries, EMSP can distribute research findings to national MS communities — a dissemination channel academic partners cannot replicate.
Both projects began in 2017, so there is no meaningful multi-year evolution to trace — the entire dataset covers a single entry cohort. The keyword set from N2B-patch (hydrogel matrix, nose-to-brain delivery, hyaluronic acid, GMP, scale-up) reflects the technical vocabulary of the consortium EMSP joined, not EMSP's own technical expertise, so these terms should be read as context rather than capability. DO-IT, running simultaneously, points toward a parallel interest in digital health and data-driven policy — suggesting EMSP was already engaged on two fronts (therapeutic innovation and health system reform) from the outset of their H2020 involvement.
With only two concurrent projects and no later-period data, no directional trend can be established — potential partners should treat EMSP as an organization with demonstrated interest in both clinical drug delivery and digital health policy, and verify their current research priorities directly.
EMSP participates exclusively as a consortium partner — never as coordinator — which is consistent with how patient organizations typically engage in EU research: contributing disease expertise and community access rather than managing scientific workflows. Despite only two projects, they built a notably wide network of 46 unique partners across 14 countries, suggesting they joined large, multi-partner consortia such as IMI projects which routinely involve 20–30 organizations. Working with EMSP means gaining a recognized patient platform, but the scientific and administrative lead will always sit with another partner.
EMSP accumulated 46 unique consortium partners across 14 countries from just two projects — an unusually broad network for an organization of this size, driven by participation in large IMI and RIA consortia. Their reach is European by design, reflecting their mandate as the pan-European MS patient umbrella.
EMSP is the only pan-European MS patient platform in the H2020 database — there is no comparable organization that combines an EU-wide MS patient mandate with demonstrated consortium experience in both pharmaceutical development (IMI) and health data policy (RIA). For any research consortium working on MS therapies, neurological disease outcomes, or patient-centered digital health, EMSP offers something that cannot be substituted: legitimate, institutionally recognized access to MS patients and caregivers across Europe. That credential also satisfies IMI and health research funding requirements for meaningful patient involvement, which is increasingly non-negotiable for project approval.
